

**CLAIMS:**

Best Available Copy

1. A transdermal spray formulation comprising:
  - a) a pharmaceutically active agent;
  - 5 b) VP/VA copolymer; and
  - c) a non-aqueous vehicle.
2. A transdermal spray formulation according to claim 1, wherein the pharmaceutically active agent is provided in a therapeutically effective amount.
- 10 3. A transdermal spray formulation according to claim 1 or 2, wherein the VP/VA copolymer is present in an amount from about 0.1% to about 20% by weight of the formulation.
- 15 4. A transdermal spray formulation according to claim 1, 2 or 3, wherein the VP/VA copolymer is present in an amount from about 0.1% to about 5% by weight of the formulation.
5. A transdermal spray formulation according to claim 1, 2, 3 or 4, wherein the 20 VP/VA copolymer is present in an amount from about 0.1% to about 2% by weight of the formulation.
6. A transdermal spray formulation according to any preceding claim, further comprising an anti-nucleating agent.
- 25 7. A transdermal spray formulation according to claim 6, wherein the anti-nucleating agent is a polyvinylpyrrolidone polymer or copolymer.
8. A transdermal spray formulation according to claim 6 or 7, wherein the anti-30 nucleating agent comprises from about 1% to about 10% by weight of the formulation.
9. A transdermal spray formulation according to any preceding claim, further comprising a penetration enhancer.

10. A transdermal spray formulation according to claim 9, wherein the penetration enhancer is selected from the group consisting of menthol, dimethylisosorbide, glycerylmono-oleate and myristyl lactate.

5

11. A transdermal spray formulation according to claim 9 or 10, wherein the penetration enhancer comprises from about 0.01% to about 5.0% by weight of the formulation.

10 12: A transdermal spray formulation according to any preceding claim, wherein the non-aqueous vehicle comprises at least about 60% by weight of the formulation.

13. A transdermal spray formulation according to any preceding claim, wherein the non-aqueous vehicle is a volatile solvent.

15

14. A transdermal spray formulation according to any preceding claim, wherein the non-aqueous vehicle is one or more of ethanol, acetone and methylal.

15. A transdermal spray formulation according to any preceding claim, wherein the 20 pharmaceutically active agent is one or more of estradiol, testosterone, oxybutynin, buprenorphine and fentanyl.

16. A transdermal spray formulation according to any preceding claim, wherein the pharmaceutically active agent is estradiol.

25

17. A transdermal spray formulation according to claim 15 or 16, wherein the estradiol is present in an amount from about 1% to about 5% by weight of the formulation.

30 18. A method of administering a pharmaceutically active agent, comprising spraying a transdermal formulation according to any one of claims 1 to 17 onto the skin of a subject in need thereof.

19. A method according to claim 18, wherein the non-aqueous vehicle volatizes upon contact with the skin, forming a film comprising the VP/VA copolymer and the pharmaceutically active agent.

5 20. A method of forming a pharmaceutically active film comprising spraying a transdermal formulation according to any one of claims 1 to 17 on the skin of a subject in need thereof.